cgp 54626 has been researched along with cyclothiazide in 1 studies
| Studies (cgp 54626) | Trials (cgp 54626) | Recent Studies (post-2010) (cgp 54626) | Studies (cyclothiazide) | Trials (cyclothiazide) | Recent Studies (post-2010) (cyclothiazide) |
|---|---|---|---|---|---|
| 57 | 0 | 16 | 396 | 4 | 51 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chavis, P; Farrugia, F; Garenne, A; Le Masson, G; Manzoni, OJ; Marsicano, G; Piet, R | 1 |
1 other study(ies) available for cgp 54626 and cyclothiazide
| Article | Year |
|---|---|
State-dependent, bidirectional modulation of neural network activity by endocannabinoids.
Topics: 4-Aminopyridine; Action Potentials; Animals; Animals, Newborn; Benzothiadiazines; Brain; Cannabinoid Receptor Modulators; Cells, Cultured; Electric Stimulation; Endocannabinoids; Excitatory Amino Acid Antagonists; GABA Antagonists; In Vitro Techniques; Mice; Mice, Transgenic; Nerve Net; Neural Inhibition; Neurons; Organophosphorus Compounds; Picrotoxin; Piperidines; Potassium Channel Blockers; Pyrazoles; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Sodium Channel Blockers; Tetrodotoxin; Valine | 2011 |